Merck Cough Drug Rejected as FDA Seeks More Information – Bloomberg

Merck & Co. said U.S. regulators declined to approve the company’s application for its experimental chronic-cough drug in its current form, a setback as the drugmaker seeks new potential blockbusters. 
The U.S. Food and Drug Administration sent Merck a complete response letter requesting additional information regarding the measurement of efficacy of the medication, gefapixant, according to a statement on Monday from the Kenilworth, New Jersey-based company. Merck said the agency’s decision wasn’t related to the safety of the drug.


Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart